NCT02076386View on ClinicalTrials.gov

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany

CompletedOBSERVATIONAL
Enrollment

411

Participants

Timeline

Start Date

March 4, 2014

Primary Completion Date

July 5, 2017

Study Completion Date

July 5, 2017

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

Dolutegravir

Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.

Trial Locations (38)

10243

GSK Investigational Site, Berlin

10405

GSK Investigational Site, Berlin

10439

GSK Investigational Site, Berlin

10707

GSK Investigational Site, Berlin

10777

GSK Investigational Site, Berlin

10961

GSK Investigational Site, Berlin

13347

GSK Investigational Site, Berlin

14057

GSK Investigational Site, Berlin

20099

GSK Investigational Site, Hamburg

20146

GSK Investigational Site, Hamburg

20246

GSK Investigational Site, Hamburg

30159

GSK Investigational Site, Hanover

39120

GSK Investigational Site, Magdeburg

40237

GSK Investigational Site, Düsseldorf

44137

GSK Investigational Site, Dortmund

44787

GSK Investigational Site, Bochum

48143

GSK Investigational Site, Münster

49090

GSK Investigational Site, Osnabrück

50668

GSK Investigational Site, Cologne

50674

GSK Investigational Site, Cologne

50679

GSK Investigational Site, Cologne

52062

GSK Investigational Site, Aachen

55116

GSK Investigational Site, Mainz

56073

GSK Investigational Site, Koblenz

60311

GSK Investigational Site, Frankfurt am Main

60590

GSK Investigational Site, Frankfurt am Main

68161

GSK Investigational Site, Mannheim

70197

GSK Investigational Site, Stuttgart

72076

GSK Investigational Site, Tübingen

79106

GSK Investigational Site, Freiburg im Breisgau

80331

GSK Investigational Site, Munich

80335

GSK Investigational Site, Munich

80336

GSK Investigational Site, Munich

80801

GSK Investigational Site, Munich

81675

GSK Investigational Site, Munich

90762

GSK Investigational Site, Fürth

99427

GSK Investigational Site, Weimar

09111

GSK Investigational Site, Chemnitz

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT02076386 - A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany | Biotech Hunter | Biotech Hunter